Matrix Metalloproteinases: Biologic Activity and Clinical Implications
Amy R. Nelson(Vanderbilt University Medical Center), Lynn M. Matrisian(Pancreatic Cancer Action Network), Barbara Fingleton(Vanderbilt University), Mace L. Rothenberg(Vanderbilt University)
Cited by 1,550
Related Papers
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
|Cancer Research|2014|7.2k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
|Science|2002|2.7k
Metalloproteinases and their inhibitors in matrix remodeling
|Trends in Genetics|1990|1.6k
The matrix‐degrading metalloproteinases
|BioEssays|1992|1.4k